Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC. | f10k123118_ex31z1.htm |
| 10-K - FORM 10-K ANNUAL REPORT - AXIM BIOTECHNOLOGIES, INC. | f10k123118_10k.htm |
| EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC. | f10k123118_ex32z1.htm |
| EX-31.2 - EXHIBIT 31.2 SECTION 302 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC. | f10k123118_ex31z2.htm |
| EX-23.1 - EXHIBIT 23.1 AUDITOR'S CONSENT - AXIM BIOTECHNOLOGIES, INC. | f10k123118_ex23z1.htm |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Report of AXIM Biotechnologies, Inc., a Nevada Corporation, (the “Company”) on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certify the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
March 15, 2018
/s/ Robert Malasek
Robert Malasek
Chief Financial Officer
Principal Financial Officer